PNAS：吸入式化疗或可对肺癌治疗有助
2010-06-06 抗癌健康网
专注健康 关爱生命 一种吸入式的鸡尾酒化疗可能有助于增加肺癌患者的存活，同时限制有害的副作用。Tamara Minko及其同事设计了一种吸入式的化学疗法，它包括了抗癌药物和设计用于抑制与化疗抗性有关基因的化合物，然后让患有多重人类肺癌肿瘤的小鼠接受了这一疗法。
这组作者报告说，这种吸入式疗法比单独使用抗癌药物或者通过静脉注射给药更成功地杀死了癌细胞并缩小了肿瘤的尺寸。测试显示，与注射相比，吸入药物的方法增强了药物与小鼠肺部的接触，并限制了在其他健康器官的毒性积累。
这组作者说，这种疗法可能有助于患者克服化疗的一些障碍，诸如癌细胞抗性、药物在肺部的浓度低，以及不良副作用。（生物谷Bioon.com）
生物谷推荐原文出处：
PNAS doi: 10.1073/pnas.1004604107
Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance
Olga B. Garbuzenkoa, Maha Saada, Vitaly P. Pozharova, Kenneth R. Reuhlb,c,d, Gediminas Mainelisc,e, and Tamara Minkoa,c,d,1
Departments of aPharmaceutics,
bPharmacology and Toxicology, and
eEnvironmental Sciences, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; c Environmental and Occupational Health Sciences Institute, Piscataway, NJ 08855; and
d Cancer Institute of New Jersey, New Brunswick, NJ 08903
Development of cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatment side effects represent main obstacles to efficient chemotherapy of lung cancer. To overcome these difficulties, we propose inhalation local delivery of anticancer drugs in combination with suppressors of pump and nonpump cellular resistance. To test this approach, nanoscale-based delivery systems containing doxorubicin as a cell death inducer, antisense oligonucleotides targeted to MRP1 mRNA as a suppressor of pump resistance and to BCL2 mRNA as a suppressor of nonpump resistance, were developed and examined on an orthotopic murine model of human lung carcinoma. The experimental results show high antitumor activity and low adverse side effects of proposed complex inhalatory treatment that cannot be achieved by individual components applied separately. The present work potentially contributes to the treatment of lung cancer by describing a unique combinatorial local inhalation delivery of drugs and suppressors of pump and nonpump cellular resistance.
这组作者报告说，这种吸入式疗法比单独使用抗癌药物或者通过静脉注射给药更成功地杀死了癌细胞并缩小了肿瘤的尺寸。测试显示，与注射相比，吸入药物的方法增强了药物与小鼠肺部的接触，并限制了在其他健康器官的毒性积累。
这组作者说，这种疗法可能有助于患者克服化疗的一些障碍，诸如癌细胞抗性、药物在肺部的浓度低，以及不良副作用。（生物谷Bioon.com）
生物谷推荐原文出处：
PNAS doi: 10.1073/pnas.1004604107
Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance
Olga B. Garbuzenkoa, Maha Saada, Vitaly P. Pozharova, Kenneth R. Reuhlb,c,d, Gediminas Mainelisc,e, and Tamara Minkoa,c,d,1
Departments of aPharmaceutics,
bPharmacology and Toxicology, and
eEnvironmental Sciences, Rutgers, The State University of New Jersey, Piscataway, NJ 08854; c Environmental and Occupational Health Sciences Institute, Piscataway, NJ 08855; and
d Cancer Institute of New Jersey, New Brunswick, NJ 08903
Development of cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatment side effects represent main obstacles to efficient chemotherapy of lung cancer. To overcome these difficulties, we propose inhalation local delivery of anticancer drugs in combination with suppressors of pump and nonpump cellular resistance. To test this approach, nanoscale-based delivery systems containing doxorubicin as a cell death inducer, antisense oligonucleotides targeted to MRP1 mRNA as a suppressor of pump resistance and to BCL2 mRNA as a suppressor of nonpump resistance, were developed and examined on an orthotopic murine model of human lung carcinoma. The experimental results show high antitumor activity and low adverse side effects of proposed complex inhalatory treatment that cannot be achieved by individual components applied separately. The present work potentially contributes to the treatment of lung cancer by describing a unique combinatorial local inhalation delivery of drugs and suppressors of pump and nonpump cellular resistance.
